Bristol-Myers Squibb

The Bristol-Myers Squibb Company and the R-Pharm Group of Companies has signed a license agreement for the localization of production of targeted anticancer therapy drug Spraysel (dasatinib) at R-Pharm enterprises.

According to a statement by Soren Giza, CEO of Bristol-Myers Squibb in Russia, the company has been cooperating with the Russian pharmaceutical manufacturers since 1992. At that time, Bristol-Myers Squibb was the first foreign pharmaceutical company that started a joint venture with the Russian manufacturer

AKRIKHIN for the production of cardiovascular drugs under license in Russia. This led to the transfer of new technologies and the creation of the country’s first industrial pharmaceutical production company that met international quality standards – GMP (Good Manufacturing Practice).

Vasily Ignatiev, CEO of R-Pharm said: “We are delighted to expand cooperation with one of the world leaders and experts in the field of high-performance products for the treatment of socially significant diseases.”

11 March 2015

Investor profile

Bristol-Myers Squibb


Company's website:

T: +1-800-321-1335

Public traded corporation BMY (NYSE)

Contact: Lamberto Andreotti, CEO

Global pharmaceutical company.